GLP-1 Evidence

Durability

What happens when you stop taking a GLP-1 drug

Most of the weight comes back. This is the most important and least advertised finding in the field, and it reframes what these drugs are for.

Updated 3 min read 21 citations Evidence strength 5/5

Loose round tablets stamped with an identifying code, seen from above
Larry D. Moore · CC BY 4.0 · Wikimedia Commons

The withdrawal experiment

STEP 1 ran for 68 weeks and then stopped the drug in everyone. The extension followed participants for a further year off treatment [5]. Having lost roughly 17% of body weight on average, participants regained about two-thirds of it within twelve months. The improvements in blood pressure, lipids and glycaemic markers moved back toward baseline on the same timescale.

This was not subtle, and it was not a subgroup. It was the central finding of the extension.

Weight regain after discontinuation

The continuation experiment

STEP 4 approached it from the other direction. Everyone ran in on semaglutide for 20 weeks; then participants were randomised either to continue or to switch to placebo [6]. Those who continued went on losing weight for the next 48 weeks. Those switched to placebo regained. Same population, same starting point, opposite trajectories, with the only difference being whether the drug continued.

Continuation versus withdrawal
TrialDesignContinued treatmentStopped treatment
STEP 1 extension [5]68 weeks on, 52 weeks off—Regained ≈ two-thirds of loss
STEP 4 [6]20-week run-in, then randomisedFurther weight lossProgressive regain
STEP 5 [4]104 weeks continuousLoss sustained to 2 years—
SELECT [3]~4 years continuousLoss sustained, events reduced—

Why this is not the scandal it is sometimes presented as

Nobody finds it damning that blood pressure rises when you stop an antihypertensive, or that cholesterol rises when you stop a statin. Obesity behaves like the chronic conditions it sits alongside: treat it, the numbers improve; withdraw treatment, they revert. The reason this lands differently is that weight is still widely understood as a character issue rather than a physiological one, so a treatment that must continue reads as failure rather than as normal chronic disease management [9].

The mechanistic reading agrees. If these drugs reset a set point, weight would not return this reliably. They suppress appetite for as long as they are present, and the appetite returns when they are not.

What this changes in practice

  • Cost is recurring, not one-off. Assess affordability over years, not over a course. This is the most common reason people stop, and stopping predicts regain.
  • Supply interruptions matter. Gaps are not neutral pauses; they are partial withdrawals.
  • Build the habits during treatment, not after. Resistance training and protein intake are far easier to establish while appetite is suppressed. Whether they meaningfully blunt regain has not been properly tested, but they are the only candidate levers available. See muscle loss.
  • Tapering has no evidence behind it. It is widely recommended and entirely untested. It may help; nobody has shown it.
  • The drugs still did something durable. Weight regain does not undo four years of reduced cardiovascular events in someone who stayed on treatment [3].
Small white coated tablets lying beside their foil blister strip
Rünno · Public domain · Wikimedia Commons

Common questions

Do I regain more than I lost?
The trial data shows regain toward baseline, not past it. Overshoot is not a finding of the withdrawal studies [5].
Does tapering the dose help?
It is plausible and completely untested. No trial has compared abrupt discontinuation with a taper.
Can I take it intermittently?
No trial has tested intermittent regimens. Given how quickly regain begins after withdrawal, there is no evidential basis for expecting it to work.
What about the lower maintenance dose?
Also untested as a distinct strategy. STEP 4 tested continuation at the full dose against placebo [6], not against a reduced dose.
Was it worth it if the weight comes back?
That depends what you were treating. If the goal was a wedding photograph, the answer may be no. If it was cardiovascular risk, the events prevented while on treatment happened and stay prevented [3].
The evidence behind this page A stacked bar showing the composition of the 21 publications cited on this page by study type. 18meta-analysis (1)randomised trial (18)review (1)other (1)
21 publications, 2016–2026. There are trials here but little synthesis, so individual results still carry a lot of weight and may move. Source: this page’s own citation list, below.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Tan HC, Dampil OA, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022 · Meta-analysis DOIPubMed 36578889Full text
  2. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Rosenstock J, Yabe D, Cox D, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41765029
  3. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  4. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38740993Full text
  5. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Bliddal H, Bays H, Czernichow S, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOIPubMed 39476339
  6. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37952131
  7. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial Rubino DM, Greenway FL, Khalid U, et al. · JAMA · 2022 · Randomised controlled trial DOIPubMed 35015037Full text
  8. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Kadowaki T, Isendahl J, Khalid U, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35131037
  9. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Heise T, Mari A, DeVries JH, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468322
  10. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Garvey WT, Batterham RL, Bhatta M, et al. · Nature medicine · 2022 · Randomised controlled trial DOIPubMed 36216945Full text
  11. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Wharton S, Calanna S, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 34514682Full text
  12. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Wilding JPH, Batterham RL, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 35441470Full text
  13. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial Wadden TA, Bailey TS, Billings LK, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33625476Full text
  14. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Rubino D, Abrahamsson N, Davies M, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33755728Full text
  15. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 34186022
  16. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial Frías JP, Auerbach P, Bajaj HS, et al. · The lancet. Diabetes & endocrinology · 2021 · Randomised controlled trial DOIPubMed 34293304
  17. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 33567185
  18. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial Sorli C, Harashima SI, Tsoukas GM, et al. · The lancet. Diabetes & endocrinology · 2017 · Randomised controlled trial DOIPubMed 28110911
  19. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Marso SP, Bain SC, Consoli A, et al. · The New England journal of medicine · 2016 · Randomised controlled trial DOIPubMed 27633186
  20. Obesity Management in Adults: A Review Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. · JAMA · 2023 · Review DOIPubMed 38015216Full text
  21. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. · JAMA internal medicine · 2024 · Journal article DOIPubMed 38976257Full text